Aminolevulinic acid - SonALAsense
Alternative Names: 5-ALA - SonALAsense; 5-Aminolevulinic acid - SonALAsense; SONALA-001Latest Information Update: 16 Jan 2025
Price :
$50 *
At a glance
- Originator SonALAsense
- Developer SonALAsense; The Ivy Brain Tumor Center
- Class Amino acids; Antianaemics; Antineoplastics; Diagnostic agents; Imaging agents; Keto acids; Levulinic acids; Nootropics; Skin disorder therapies; Small molecules; Vascular disorder therapies
- Mechanism of Action Photosensitisers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma
- Preclinical Cancer
- Suspended Glioma
Most Recent Events
- 16 Jan 2025 Chemical structure information added.
- 30 Jul 2024 Suspended - Phase-II for Glioma (In adolescents, In children, In the elderly, In adults) in USA (IV) (NCT05123534)
- 08 Jul 2024 SonALAsense terminates a phase-II trial in Glioblastoma (Combination therapy, Recurrent, Second-line therapy or greater) in USA (IV) due to funding challenges (NCT05370508)